Latest updates

6 October

2017

Bulletins

CJEU rules on effect of product indication on EU registered designs

Helpfully for applicants of EU registered designs the Court of Justice of the European Union (CJEU) has confirmed that the product indication of an EU registered design limits neither the scope of protection nor the citable prior art. It will be appreciated that a design can be applied to various different products (for example, a

4 October

2017

Bulletins

Virtual marking of products covered by a registered design

As a result of aspects from the Digital Economy Act coming into effect on 1 October 2017, UK legislation now expressly provides for the use of virtual marking on products covered by  a UK registered design. Under current legislation, an infringer of a UK registered design (UKRD) who can prove that at the date of the

15 September

2017

Bulletins

New threats provisions in the UK

The United Kingdom is one of the few jurisdictions to have provisions within the trade mark law relating to the making of unjustified threats. The aim of these provisions is to encourage trade mark proprietors to write to, and engage with, the primary infringer (generally the party attaching the infringing mark to the goods or

13 September

2017

Bulletins

European Commission’s position paper on IP Rights post Brexit

The European Commission’s Task Force for Brexit negotiations published its position paper on intellectual property rights (including geographical indications) on 6 September 2017. At present, the UK Government has not issued a reciprocal paper and until a formal Withdrawal agreement is concluded between the European Commission and the UK government, the post‑Brexit application of unitary

6 September

2017

Bulletins

Plausibility – EPO confirms requirements for using post-filed data to support a technical effect

The EPO’s Board of Appeal recently revoked a patent covering Bristol-Myers Squibb’s blockbuster oncology drug dasatinib (marketed as Sprycel®). This decision (T488/16) provides valuable guidance into avoiding the pitfalls, and exploiting third party vulnerabilities, associated with the issue of plausibility. Plausibility is central to a number of statutory requirements to patentability at the EPO including

1 2 3 48

Events

December 2017

Attendee: Jennifer O’Farrell

Westminster Health Forum Keynote Seminar: The future of personalised and genomic medicine, London, December 2017

UCL IBIL Debate ‘Equivalents: K = Na. Is the genie out of the bottle?’, London, November 2017

November 2017

Attendee: Matthew Spencer

CIPA Life Sciences Conference, Speaker, Northampton, November 2017

November 2017

Attendee: Peter Vaughan

MarkMonitor 7th annual domain seminar, London, November 2017

November 2017

Attendee: Emma Pitcher

INTA Annual Leadership Meeting, Washington, November 2017

November 2017

Attendee: Jennifer O’Farrell

BIO-Europe 2017, Berlin, Germany, November 2017

October 2017

Attendees: Adrian Hayes, Joanna Peak

AIPLA Annual Meeting, Washington, October 2017

October 2017

Attendee: Luke Portnow

Journal of Intellectual Property Law & Practice (JIPLP) and German Association for the Protection of Intellectual Property (GRUR)

October 2017

Attendee: Luke Portnow

Journal of Intellectual Property Law & Practice (JIPLP) and German Association for the Protection of Intellectual Property (GRUR)

October 2017

Attendee: Claire Baldock

AIPPI World Congress 2017, Sydney, Australia, October 2017

October 2017

Attendee: Jennifer O’Farrell

BIA UK Bioscience Forum, Speaker, London, October 2017

Hover to read more

Jennifer will be co-presenting on the session entitled ‘Developing and delivering Advanced Therapies – clinical trials are just the start’, which will discuss how to use patents to secure the value of your product, ways to streamline your supply chain and how to obtain market access and reimbursement.

October 2017

Attendee: Emma Pitcher

IPIC 91st Annual Meeting, Panellist, Ottawa, Canada, October 2017

Hover to read more

Emma will be on the panel discussing ‘Sounds, Scents, Flavours — An Update on Non-Traditional Marks in Canada, the US and the EU’.

October 2017

Attendees: Edward Ronan, Nadia Tyler-Rubinstein

BioBeat17 Meeting, London, November 2017

October 2017

Attendee: Edward Ronan

London IP Summit, Attending, October 2017

boult.bites

boult.bites TM – Autumn 2017

In this issue of boult.bites we cover: Thailand becoming the 99th member of the Madrid Protocol, Brewdog Plc’s failed attempt to register the phrase ELVIS JUICE; a breakthrough for China and the EU in coming to an agreement on the protection of GI’s; and, finally, BMW’s appeal against the decision taken concerning the use of their marks by TLL.

boult.bites Biotech – Autumn 2017

The ten minute read that highlights topical issues for bio and life science sector participants

boult.bites TM – Summer 2017

In this edition of Boult. bites, we look back INTA 2017; we look at what constitutes ‘similar and/or complementary good and services’; we advise on maintaining trade mark rights in the EU, and finally highlight an often overlooked ground of revocation that trade mark owners should be aware of.

Industry news

Guest posts from other sources. Clicking on the links will take you to an external site.

Search